Bausch Health Cos Inc. (NYSE:BHC) Receives $8.50 Average PT from Analysts

Bausch Health Cos Inc. (NYSE:BHC) has been assigned an average rating of “Hold” from the six ratings firms that are covering the firm, Marketbeat.com reports. Six analysts have rated the stock with a hold rating. The average 1 year target price among analysts that have covered the stock in the last year is $8.50.

A number of equities analysts have commented on BHC shares. Truist Financial raised their price objective on Bausch Health Cos from $7.00 to $8.00 and gave the stock a “hold” rating in a research note on Wednesday, January 7th. Wall Street Zen downgraded Bausch Health Cos from a “strong-buy” rating to a “buy” rating in a research report on Saturday. Raymond James Financial raised Bausch Health Cos to a “hold” rating in a report on Monday, December 15th. Barclays started coverage on Bausch Health Cos in a research report on Monday, December 8th. They issued an “equal weight” rating and a $8.00 price target on the stock. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Bausch Health Cos in a research report on Monday, December 29th.

Bausch Health Cos Stock Performance

Shares of NYSE:BHC opened at $6.98 on Friday. Bausch Health Cos has a 12-month low of $4.25 and a 12-month high of $8.69. The company’s 50 day moving average price is $6.90 and its two-hundred day moving average price is $6.78. The firm has a market cap of $2.59 billion, a PE ratio of 7.20 and a beta of 0.37. The company has a quick ratio of 0.97, a current ratio of 1.30 and a debt-to-equity ratio of 57.48.

Institutional Trading of Bausch Health Cos

Several large investors have recently made changes to their positions in the company. Range Financial Group LLC increased its stake in Bausch Health Cos by 8.8% in the fourth quarter. Range Financial Group LLC now owns 175,996 shares of the company’s stock valued at $1,223,000 after acquiring an additional 14,223 shares during the last quarter. Kathmere Capital Management LLC acquired a new stake in shares of Bausch Health Cos in the 4th quarter valued at $89,000. Swiss Life Asset Management Ltd bought a new position in shares of Bausch Health Cos in the 3rd quarter valued at $72,000. Goldentree Asset Management LP increased its stake in shares of Bausch Health Cos by 1.7% in the 3rd quarter. Goldentree Asset Management LP now owns 34,833,431 shares of the company’s stock valued at $224,409,000 after purchasing an additional 578,542 shares during the last quarter. Finally, CANADA LIFE ASSURANCE Co raised its holdings in shares of Bausch Health Cos by 4.1% during the 3rd quarter. CANADA LIFE ASSURANCE Co now owns 108,393 shares of the company’s stock worth $699,000 after buying an additional 4,237 shares in the last quarter. Institutional investors and hedge funds own 78.65% of the company’s stock.

Bausch Health Cos Company Profile

Bausch Health Cos Inc, formerly known as Valeant Pharmaceuticals International, is a global specialty pharmaceutical company headquartered in Laval, Quebec, Canada. The company operates through two primary segments: Ophthalmology, led by its Bausch + Lomb franchise, and Diversified Brands, which encompasses prescription dermatology, gastrointestinal, neurology and branded pharmaceutical products. Bausch Health develops, manufactures and markets a range of therapeutic and over-the-counter offerings designed to address conditions such as cataracts, dry eye, glaucoma, acne, rosacea, migraine and gastrointestinal disorders.

The Ophthalmology segment under the Bausch + Lomb name provides products for eye health, including prescription drops, contact lens care solutions, intraocular lenses, surgical instruments and diagnostic devices.